---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-23-005510"
form_type: "8-K"
ticker: "AEMD"
cik: "0000882291"
company_name: "AETHLON MEDICAL INC"
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T20:58:10.221897+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Aethlon Medical Q1 FY2024 net loss $3.3M, cash $12.9M; Hemopurifier progress

## Summary
- Net loss widened to $3.3M for quarter ended June 30, 2023 from $2.9M a year ago; operating expenses rose 17.3% to $3.4M.
- Cash balance $12.9M at quarter end; raised $1.1M net proceeds via at-the-market equity facility with H.C. Wainwright.
- COVID-19 ICU trial in India remains open; second site Maulana Azad Medical College received Ethics Board approval.
- Entered research collaboration with 34 Lives to test Hemopurifier in machine perfusion of recovered kidneys.
- Oncology feasibility trial in Australia with NAMSA for solid tumors failing anti-PD-1 therapy is ongoing.

## SEC filing metadata
- accession: 0001683168-23-005510
- form_type: 8-K
- ticker: AEMD
- cik: 0000882291
- company_name: AETHLON MEDICAL INC
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882291/000168316823005510/0001683168-23-005510-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882291/000168316823005510/aethlon_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-23-005510
- JSON: https://secwatch.observer/filing/0001683168-23-005510.json
- Plain text: https://secwatch.observer/filing/0001683168-23-005510.txt

## Key facts
- Earnings Releases
  AETHLON MEDICAL INC reported first quarter ended June 30, 2023 results: net income approximately $3.3 million.
  - Period: first quarter ended June 30, 2023
  - Net income: approximately $3.3 million
  - Result: reported results
  source text: As a result of the above factors, the company’s net loss increased to approximately $3.3 million in the three months ended June 30, 2023, from approximately $2.9 million in the three months ended June 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/882291/000168316823005510/0001683168-23-005510-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.